Patents by Inventor Michael K. Ameriks
Michael K. Ameriks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11993601Abstract: Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R2, R3 R4, R5 and R6 are defined herein.Type: GrantFiled: January 27, 2023Date of Patent: May 28, 2024Inventors: Michael K. Ameriks, Gang Chen, Chaofeng Huang, Brian Ngo Laforteza, Suchitra Ravula, Wei Zhang
-
Publication number: 20240092781Abstract: Aryl piperidine compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R2a, R2b, R3, R4, R5a and R5b are as defined herein.Type: ApplicationFiled: September 21, 2023Publication date: March 21, 2024Inventors: Michael K. Ameriks, Cynthia B. Berry, Krisztián Biró, Pablo Garcia-Reynaga, Andrew V. Samant, Warren S. Wade
-
Patent number: 11919870Abstract: Aminocyclobutane compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R1, R2a, R2b, R3 and R4 are defined herein.Type: GrantFiled: October 31, 2022Date of Patent: March 5, 2024Assignee: Janssen Pharmaceutica NVInventors: Michael K. Ameriks, Pablo Garcia-Reynaga
-
Patent number: 11897872Abstract: Azaspirocycle compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R1, R2a, R2b, R3, m, n, o, and p are defined herein.Type: GrantFiled: October 31, 2022Date of Patent: February 13, 2024Assignee: Janssen Pharmaceutica NVInventors: Jesus Alcazar, Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Andrew V. Samant, J. A. Vega-Ramiro
-
Patent number: 11891387Abstract: Fused and bridged compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein R1a, R1b, R2, and R3, are defined herein.Type: GrantFiled: March 25, 2021Date of Patent: February 6, 2024Assignee: Janssen Pharmaceutica NVInventors: Michael K. Ameriks, Brian Ngo Laforteza, Suchitra Ravula, Jamie M. Schiffer, Brice M. Stenne
-
Publication number: 20230382902Abstract: 3.1.0 and 4.1.0 Azabicycle compounds of Formula (I), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein X, Y, R1, R2a, and R2b are defined herein.Type: ApplicationFiled: June 2, 2023Publication date: November 30, 2023Inventors: Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Brian Ngo Laforteza, Jimmy T. Liang
-
Patent number: 11820766Abstract: Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.Type: GrantFiled: December 23, 2020Date of Patent: November 21, 2023Assignee: Janssen Pharmaceutica NVInventors: Michael K. Ameriks, Gang Chen, Chaofeng Huang, Brian Ngo Laforteza, Suchitra Ravula, Emma Helen Southgate, Wei Zhang
-
Patent number: 11802111Abstract: Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to depression, major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, and bipolar disorder), cancers and eye conditions: wherein R1, , R3, and L are as defined herein.Type: GrantFiled: September 21, 2021Date of Patent: October 31, 2023Assignee: Janssen Pharmaceutica NVInventors: Jesus Alcazar, Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Brian Ngo Laforteza, Andrew V. Samant
-
Publication number: 20230331686Abstract: Aminocyclobutane compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R1, R2a, R2b, R3 and R4 are defined herein.Type: ApplicationFiled: October 31, 2022Publication date: October 19, 2023Inventors: Michael K. Ameriks, Pablo Garcia-Reynaga
-
Patent number: 11787798Abstract: Aryl piperidine compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R2a, R2b, R3, R4, R5a and R5b are as defined herein.Type: GrantFiled: March 25, 2021Date of Patent: October 17, 2023Assignee: Janssen Pharmaceutica NVInventors: Michael K. Ameriks, Cynthia B. Berry, Krisztián Biró, Pablo Garcia-Reynaga, Andrew V. Samant, Warren S. Wade
-
Publication number: 20230242531Abstract: Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R2, R3 R4, R5 and R6 are defined herein.Type: ApplicationFiled: January 27, 2023Publication date: August 3, 2023Inventors: Michael K. Ameriks, Gang Chen, Chaofeng Huang, Brian Ngo Laforteza, Suchitra Ravula, Wei Zhang
-
Patent number: 11708359Abstract: 3.1.0 and 4.1.0 Azabicycle compounds of Formula (I), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein X, Y, R1, R2a, and R2b are defined herein.Type: GrantFiled: February 9, 2021Date of Patent: July 25, 2023Assignee: Janssen Pharmaceutica NVInventors: Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Brian Ngo Laforteza, Jimmy T. Liang
-
Publication number: 20230227438Abstract: Azaspirocycle compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R1, R2a, R2b, R3, m, n, o, and p are defined herein.Type: ApplicationFiled: October 31, 2022Publication date: July 20, 2023Inventors: Jesus Alcazar, Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Andrew V. Samant, J. A. Vega-Ramiro
-
Publication number: 20230145249Abstract: Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.Type: ApplicationFiled: December 6, 2022Publication date: May 11, 2023Inventors: Michael K. Ameriks, Gang Chen, Chaofeng Huang, Brian Ngo Laforteza, Suchitra Ravula, Emma Helen Southgate, Wei Zhang
-
Publication number: 20230110576Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).Type: ApplicationFiled: October 17, 2022Publication date: April 13, 2023Inventors: Michael K. Ameriks, Gang Chen, Bradley M. Savall, Devin M. Swanson, Wei Zhang, Dongpei Wu
-
Publication number: 20230114165Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).Type: ApplicationFiled: October 17, 2022Publication date: April 13, 2023Inventors: Michael K. Ameriks, Gang Chen, Bradley M. Savall, Devin M. Swanson, Wei Zhang, Dongpei Wu
-
Patent number: 11597728Abstract: Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R2, R3 R4, R5 and R6 are defined herein.Type: GrantFiled: December 23, 2020Date of Patent: March 7, 2023Assignee: Janssen Pharmaceutica NVInventors: Michael K. Ameriks, Gang Chen, Chaofeng Huang, Brian Ngo Laforteza, Suchitra Ravula, Wei Zhang
-
Patent number: 11512059Abstract: Aminocyclobutane compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R1, R2a, R2b, R3 and R4 are defined herein.Type: GrantFiled: March 25, 2021Date of Patent: November 29, 2022Assignee: Janssen Pharmaceutica NVInventors: Michael K. Ameriks, Pablo Garcia-Reynaga
-
Publication number: 20220372030Abstract: Fused and bridged compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein R1a, R1b, R2, and R3, are defined herein.Type: ApplicationFiled: March 25, 2021Publication date: November 24, 2022Inventors: Michael K. Ameriks, Brian Ngo Laforteza, Suchitra Ravula, Jamie M. Schiffer, Brice M. Stenne
-
Patent number: 11505546Abstract: Azaspirocycle compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R1, R2a, R2b, R3, m, n, o, and p are defined herein.Type: GrantFiled: March 25, 2021Date of Patent: November 22, 2022Assignee: Janssen Pharmaceutica NVInventors: Jesus Alcazar, Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Andrew V. Samant, J. A. Vega-Ramiro